NYSE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Cel-sci Corporation CVM
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-6.27
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-176.3%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD -6.27
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-176.3%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-92.2%
Each USD of equity lost 176 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−34.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+69.2%
Change, 10 years—
The share count grew 69% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 28.2M
total assets, end of FY2025
Total assetsUSD 28.2M
EquityUSD 16.0M
CashUSD 11.0M
Gross debtUSD 5.7M
Net debtUSD -5.3M
Current ratio2.26×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
EPS, diluted $
−6.27
−15.31
−0.73
−0.87
−0.90
−0.82
−0.71
−1.87
−1.91
−2.37
−10.51
−12.21
−0.66
−0.78
−1.49
0.06
−0.31
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−176.3
−206.4
−142.6
−82.8
−95.4
−243.4
−862.2
·
·
·
−1152.3
−312.9
−133.6
−192.2
−139.2
57.1
−462.7
Shares out B
0.01
0.00
0.05
0.04
0.04
0.04
0.04
0.03
0.01
0.01
0.00
0.08
0.03
0.03
0.21
0.20
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed